مباشر

Clinical OMICsTwo Women, One Mission: Closing the Gap Between Cancer Science and Survival Endpoints NewsTakeda fortifies orexin potential with more Phase 3 data Endpoints NewsElicio’s KRAS cancer vaccine fails in Phase 2, shares plummet FierceBiotechAmid US investment tour, J&J makes $1B stop in Florida to upgrade contact lens plant Endpoints NewsGan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma data FierceBiotechAmgen loses in Harbour antibody patent case, ordered to pay $20M+FierceBiotechIntellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatment BioWorldElicio phase II results in pancreatic cancer wreck shares BioWorldBiggest gainers and losers for June 8-12, 2026 FierceBiotechNeumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studies Endpoints NewsNeumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff Clinical OMICsRewriting Cancer Care Through Epigenetics

FierceBiotech ١٥ يونيو ٢٠٢٦

Amgen loses in Harbour antibody patent case, ordered to pay $20M+

A federal jury in Delaware has found that Amgen and its acquired Teneobio willfully infringed on an antibody patent held by Harbour Antibodies, a Dutch subsidia...

A federal jury in Delaware has found that Amgen and its acquired Teneobio willfully infringed on an antibody patent held by Harbour Antibodies, a Dutch subsidiary of China’s Harbour BioMed.